The first time I took Afrezza––an inhalable fast-acting insulin––in public, it was at Wildair, a small, hip restaurant i…
Oral Insulin
MannKind Markets Afrezza to People with Type 1 Diabetes
The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on d…
Novo Nordisk Drops Oral Insulin Development Projects
According to an article published on Seeking Alpha, Novo Nordisk has decided to make some significant changes in its dru…
Sanofi Licenses Afrezza Inhaled Insulin from MannKind
Sanofi and MannKind Corporation have entered into a worldwide exclusive licensing agreement for development and commerci…
Inhaled Insulin for Diabetes: Is Afrezza Worth the Risks?
Will I prescribe Afrezza for people with diabetes? Not a lot, and not for past or present smokers, and not for people w…
FDA Approves Afrezza Rapid-Acting Inhaled Insulin
The U.S. FDA approved Mannkind Corporation's Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin, …
FDA Advisory Committee Recommends Approval of Mannkind’s Inhaled Insulin, Afrezza
The U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that Afrezza (insulin hu…
MannKind Seeks FDA Approval for Inhaled Insulin
MannKind Corporation has resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking…
Positive Results for Mannkind’s Inhaled Insulin, Afrezza
MannKind Corporation has announced that it has positive preliminary results from two Phase 3 clinical studies of Afrezza…
FDA Clears Oramed’s Oral Insulin for Trial
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and …
